Generate Biomedicines (GENB) Stock Price, News & Analysis

Company Overview

Generate Biomedicines, Inc. (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates. The company pursues internally discovered programs while also collaborating with biopharmaceutical partners to apply its platform to target-specific problems. Its work spans de novo protein design, engineered biologics and other molecular modalities, with an emphasis on accelerating early-stage development and generating candidates for preclinical advancement.

Headquartered in the United States, Generate serves the broader global biotech and pharmaceutical community through its direct programs and strategic collaborations. The company is publicly traded on the NASDAQ under the ticker GENB and positions itself as a platform-driven innovator in the emerging field often described as generative biology. Management and scientific leadership are built around experience in computational biology and drug discovery, supporting the company’s focus on integrating AI methods into the conventional drug development pipeline.

Key Stats

• Today's Range: $14.74 to $16.30
• 50-Day Range: $13.08 to $20.38
• 52-Week Range: $11.00 to $22.67
• Volume: 2.35 million shs
• Average Volume: 1.18 million shs
• Market Capitalization: $1.97 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.40
• Consensus Rating: Moderate Buy

Generate Biomedicines Stock Analysis - MarketRank™

Generate Biomedicines scored higher than 44% of companies evaluated by MarketBeat, and ranked 660th out of 919 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Generate Biomedicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Generate Biomedicines has a consensus price target of $26.40, representing about 72.2% upside from its current price of $15.33.

Amount of Analyst Coverage

Generate Biomedicines has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Generate Biomedicines are expected to grow in the coming year, from ($2.29) to ($2.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Generate Biomedicines is -9.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Generate Biomedicines is -9.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Generate Biomedicines has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.68% of the float of Generate Biomedicines has been sold short.

Short Interest Ratio / Days to Cover

Generate Biomedicines has a short interest ratio ("days to cover") of 15.09, which indicates bearish sentiment.

Change versus previous month

Short interest in Generate Biomedicines has recently increased by 0.15%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Generate Biomedicines does not currently pay a dividend.

Dividend Growth

Generate Biomedicines does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.48

News Sentiment

Generate Biomedicines has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Generate Biomedicines this week, compared to 2 articles on an average week.

Search Interest

Only 6 people have searched for GENB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

6 people have added Generate Biomedicines to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Generate Biomedicines insiders have not sold or bought any company stock.

Percentage Held by Institutions

Generate Biomedicines has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GENB
• CIK: 2100782
• Web: www.generatebiomedicines.com
• Phone: (888) 469-0055
• Fax: N/A
• Employees: 312
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Generate Biomedicines: $26.40
• High Price Target: $30.00
• Low Price Target: $22.00
• Potential Upside/Downside: +72.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.30
• Quick Ratio: 8.30

Sales & Book Value

• Annual Sales: $31.89 million
• Price / Sales: 61.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.55 per share
• Price / Book: 4.32

Miscellaneous

• Outstanding Shares: 128,350,000
• Free Float: N/A
• Market Cap: $1.97 billion
• Optionable: N/A
• Beta: N/A